DE hit a new 52-week high on May 27. Not likely to go higher during the next few months. AG sector weakness is expected to continue into next year or even 2017. Time to take profits, and perhaps buy back later at a lower price.
Time for a bounce. HPQ oversold. HPQ going to $35.27 to $35.87 next week, at least for a moment.
Come on friends. I need my 13Mar $34 calls to have a bit of a profit. Cost me 50 cent.
The ARUN acquisition must spark a little enthusiasm for HPQ. Seems like a positive move for HPQ, and Meg made a good deal--IMHO.
Very true. No top line growth. Bottom line has improved since 2012. Hopefully, ARUN will add revenue and profits. Seems like a good acquisition at a fair price.
I agree that HPQ did not overpay for ARUN. $2.7B was reasonable--about 3x current revenue.
That said, $2.7B is a lot of money and the acquisition will take several years for HPQ to recover cost, and there is no guarantee. "Pricey" but not "over-priced" .
ARUN is a fast growing business that fits well into HPQ businesses. ARUN financials last quarter: sales of $210M last quarter, gross profit of $160M and overhead expenses of $90M, operating income of $21M and net income of $6M. The overhead expenses can be reduced and the sales increased with ARUN merged into HPQ--positive synergy in likely. The $2.7B purchase is a bit pricey, but the ARUN business profits might pay for the acquisition in less than five years--provided that HPQ management does not ruin ARUN innovation and momentum.
Meg Whitman is an effective leader, and she has done will running HPQ to date--IMHO. HPQ is currently oversold and undervalued. Give HPQ a PE of 15, and the price would be around $39. The average PE for the S&P 500 is about 17.
I expect that many of the 22.5M shares were shares sold short, naked. Goldman Sachs is usually right in their predictions of stock price. MNKD longs should be worried as the number of people on Afrezza are few. Talk by Sanofi and Mannkind regarding samples is nice, but prescriptions is the revenue stream. We need big growth in person using Afrezza within the next two or three months. Tell you diabetic friends to give Afrezza a try.
Goldman Sachs is a heavy. They tend to be right.
The number of scripts to date is not inspiring--about 300 to date.
The fact that the incidence of hypoglycemia is much lower when using Afrezza is very significant.
The fact mealtime insulin via Afrezza is superior is significant.
These two benefits are not on the label, but will be experienced by patients and doctors, but that will take time.
Cough incidence is low, but gets hyped.
I am very disappointed in the scripts to date, and worried.
Goldman Sachs downgrade is based on the lack of scripts. When will the scripts volume improve? Ever?
We need a big jump very soon, or Sanofi might give Afrezza back to Mannkind, which might doom MNKD.
A scripts count over 10,000 by May would be nice to see.
Some of the $3B annual sales of the now defunct Radio Shack will migrate to Best Buy.
The Radio Shack bankruptcy and closure is a net positive for Best Buy.
Best Buy has adjusted business processes and makes money.
I am gaming for a run to $43 after earnings on March 3.